Nothing from AASLD leads me to think Boceprevir has narrowed the gap relative to Telaprevir. MRK needs to find a sustainable marketing angle to avert having Boceprevir become a commercial bust. Comments?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”